Navigation Links
Additional Data on CombinatoRx Drug Candidates CRx-102 and CRx-139,Presented at EULAR

ritis". Additional analysis from the trial indicated that CRx-102 treated patients experienced significantly less fatigue than those on placebo (-27.2mm CRx-102 vs. -14.3mm placebo, p=0.03). Fatigue information was collected on all subjects in the trial and was measured using a visual analog scale (VAS).

"This data on CRx-102 provides additional evidence of its clinical benefit and novel mechanism of action which will prove extremely helpful as we design future studies and more specifically define the clinical benefit of CRx-102 and its potential role within the RA and OA treatment paradigms," commented Alexis Borisy, President and CEO of CombinatoRx.

CRx-139

Also, during the satellite symposium, Dr. Paul Emery of Leeds Teaching Hospital in the UK gave a talk entitled "Inverting the Pyramid, Deploying Smarter Combination Therapies in RA", during which he presented additional analysis from the recently completed phase 2a clinical trial of CRx-139. Dr. Emery showed that subjects treated with high dose CRx-139 (3mg of prednisolone and 20mg of paroxetine) showed a benefit in ACR 50 response compared to low dose CRx-139 (3mg of prednisolone and 10mg of paroxetine) or 3mg of prednisolone alone.

-- ACR 50 at day 42 (32% CRx-139 high dose vs. 13% CRx-139 low dose and 13% 3mg prednisolone, p=0.008)

-- ACR 50 at day 70 (28% CRx-139 high dose vs. 15% CRx-139 low dose and 20% 3mg prednisolone, p=NSS)

Dr. Emery also noted that a subset of the high dose treated patients experienced durable remission defined as DAS28 score of less than 2.6 at consecutive visits (19% CRx-139 high dose vs. 4% CRx-139 low dose and 3% 3mg prednisolone, p=0.026).

About CRx-102

CRx-102 is an oral synergistic combination drug candidate containing the cardiovascular agent dipyridamole and an unconventionally low dose of the steroid prednisolone. CRx-102 works through a novel mechanism of action in which dipyridamole selectively amplifies prednisolone
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
2. Cytokinetics Reports Additional Clinical Trials Data for Ispinesib
3. Further Statistical Analysis of the Recent Phase III trial on Lead Product M6G Shows Additional Benefits
4. Novel Mechanism Insights and Additional Data on CombinatoRx Drug Candidates to Be Presented at Upcoming EULAR Meeting
5. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
6. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
7. Cell Genesys Reports Additional Data From Phase 2 Clinical Trial of GVAX Immunotherapy for Pancreatic Cancer
8. Additional New Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at ASCO Annual Meeting
9. New Study Results Provide Additional Data about Short- and Long-Term Use of Desvenlafaxine Succinate in the Treatment of Adults with Major Depressive Disorder
10. Additional Efficacy Data from Satraplatin SPARC Phase 3 Investigational Trial Presented at Annual Meeting of American Urological Association
11. PTC Therapeutics Announces Additional Positive Interim Phase 2 Results of PTC124 in Duchenne Muscular Dystrophy
Post Your Comments:
(Date:9/4/2015)... 4, 2015  Pharmaceutical companies today rely heavily ... Medical Specialists (FBMS) to build and strengthen vital ... leaders in critical therapeutic areas. ... companies are expanding the critical MSL function into ... corporate objectives and to achieve regional consistency, compliance, ...
(Date:9/4/2015)... , Sept. 4, 2015  Essilor is pleased to ... greatest defense against the eyestrain that comes with the ... to serve as an everyday pair of glasses to ... who are on smart phones, tablets and computers for ... those who require a prescription but also those who ...
(Date:9/4/2015)... , Sept. 4, 2015  Orexigen® Therapeutics, Inc. (Nasdaq: ... overview at the Wells Fargo Securities 2015 Healthcare Conference in ... Thursday, September 10 th at 2:30 p.m. Eastern Time. ... the discussion, please visit the Investors section of the Company,s ... available for 14 days after the event.  Orexigen ...
Breaking Medicine Technology:New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2Essilor Launches New Eyezen Glasses Specifically Designed For A Digital Focused Audience 2
... 2011 Baxano, Inc., a Silicon Valley based medical ... spinal decompression surgery, announces a rapid expansion of its ... products. This continued expansion in the ... and existing accounts throughout the U.S. while providing greater ...
... Johnson & Johnson Pharmaceutical Research & Development, L.L.C. ... New Drug Application (sNDA) to the U.S. Food and ... extended-release tablets, an oral analgesic, for the management of ... adults. The FDA approved NUCYNTA ® ER on ...
Cached Medicine Technology:Baxano Rapidly Expands Sales Force to Support Robust Demand for the iO-Flex® System 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 2Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 3Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 4Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 5Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 6Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 7Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 8Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 9Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 10Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 11Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 12Supplemental New Drug Application Submitted to FDA for NUCYNTA® ER (Tapentadol) Extended-Release Tablets for Diabetic Peripheral Neuropathic Pain 13
(Date:9/4/2015)... , ... September 04, 2015 , ... Lalonde Gordon ran ... and followed up with victory in the men’s 400 meters final, with an impressive ... and Field Championships in San Jose, Costa Rica in August 2015. The 44.64 time ...
(Date:9/4/2015)... ... September 04, 2015 , ... Yisrayl Hawkins, Pastor and Overseer at The House of Yahweh, has ... involving the Pope’s upcoming trip to the United States. , Yisrayl lays out what he ... the Vatican and society is. Yisrayl also provides the meaning of his own name and ...
(Date:9/4/2015)... ... ... Friday night, Chicago lovebirds Jenny McCarthy and Donnie Wahlberg celebrated their one-year ... families affected by autism, raising nearly $250,000. , 150 guests, including event co-chairs ... Swan Inn to support the cause. , McCarthy tugged the heartstrings of everyone ...
(Date:9/3/2015)... ... September 03, 2015 , ... Allied Anesthesia is proud to ... is the norm not the exception. , St. Jude was recently named one of ... Stroke Association, making it one of only 10 hospitals in the state to earn ...
(Date:9/3/2015)... New York (PRWEB) , ... September 03, 2015 , ... ... Do”. William Mattar, Esq. believes this does not stop at any certain demographic ... captioning to its newly produced one-minute, thirty-, fifteen- and ten-second TV commercials. , The ...
Breaking Medicine News(10 mins):Health News:Lalonde Gordon’s Recipe Brings Home the Gold 2Health News:Lalonde Gordon’s Recipe Brings Home the Gold 3Health News:Yisrayl Hawkins Writes Open Letter to Pope Francis In Light of Approaching U.S. Visit 2Health News:Jenny McCarthy & Donnie Wahlberg Help Raise Over $200,000 For Generation Rescue’s ‘Night Of Hope’ Chicago Charity Event 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 2Health News:Allied Anesthesia Physicians Announce Partnership with St. Jude 3Health News:Law Firm Focused on “Helping People” Continues to Expand on Vision 2
... ophthalmologist at UT Southwestern Medical Center has helped create a ... disease better track vision changes. With the hand-held digital ... in less than 90 seconds, said Dr. Yu-Guang He, associate ... do not have timely eye exams and end up suffering ...
... [EMBARGOED FOR JULY 26, 2011] Antibiotic overuse and resistance ... decades. Following an outbreak of Clostridium difficile infections, which ... Quebec, Canada targeted physicians and pharmacists with an education ... study published in Clinical Infectious Diseases and ...
... July 25 (HealthDay News) -- Parents of children with attention-deficit/hyperactivity disorder ... than 10 years old with ADHD may be unable to cross ... that while children with ADHD may look as if they are ... look both ways before crossing -- they aren,t always good at ...
... gravel roads in Dunn County, North Dakota, they stir up ... wake contain such high levels of the mineral erionite that ... an increased risk of developing mesothelioma, a type of cancer ... is a natural mineral fiber that shares similar physical similarities ...
... July 25 (HealthDay News) -- Although many Americans continue ... likely to remain on the job after they turn ... The researchers also found that lower-income workers are ... particularly arthritis, later in life. As a result, the ...
... MONDAY, July 25 (HealthDay News) -- People who resume smoking ... die than those who quit for good, a new Italian ... relapsed were three to five times more likely to die ... need to do more to support long-term ,smoking-cessation efforts after ...
Cached Medicine News:Health News:UT Southwestern ophthalmologist helps develop device for monitoring degenerative eye disease 2Health News:Simple guidelines decreased unnecessary antibiotic use in Quebec, Canada 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 2Health News:Kids With ADHD Less Adept at Crossing the Street: Study 3Health News:New study finds cancer-causing mineral in US road gravel 2Health News:New study finds cancer-causing mineral in US road gravel 3Health News:Blue-Collar Employees With Arthritis Working Past 65: Study 2Health News:Smoking After Heart Attack Raises Risk of Dying 2
... VERSASTEP™ Plus Short Instrument ... , ,The VERSASTEP™ Plus ... Working Length is a unique ... applications in laparoscopic procedures. It ...
... Trocar consists of a blunt obturator connected ... assembly. , ,The valve body assembly ... to prevent gas leakage when instruments are ... Trocar includes built-in converters to allow insertion ...
... Premium One-Step™ single-use system device is comprised ... device components for creating each access port ... , Step™ insufflation and access needle, ... separately. , Step™ radially expandable sleeve, 100 ...
... contains an internal seal to prevent gas leakage ... of pneumoperitoneum. The 5 mm PLUS system includes ... mm - 12 mm as appropriate and is ... of the trocar to allow insertion of smaller ...
Medicine Products: